Fig. 2.
Relationship between gastric acid exposure (AUCpH<3) during betaine HCl treatment and change in dasatinib Cmax and AUC during rabeprazole-induced hypochlorhydria. The changes in dasatinib Cmax, AUC0–22, and AUC0−∞were calculated by taking the ratio of each parameter during treatment C (dasatinib + rabeprazole + betaine HCl) relative to treatment B (dasatinib + rabeprazole). AUCpH<3, a measure of overall gastric acid exposure, was calculated as previously described (16). Data from one subject was excluded from these comparisons as the terminal phase of dasatinib pharmacokinetics could not be estimated during treatment B